Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

All of the following criteria must be met in order to be enrolled in the study:

- Age ≥18 years
- Life expectancy ≥6 months
- Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade <=1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- · Breast cancer only:
- Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)
- Planned minimum of 6 cycles of chemotherapy
- · Lymphoma only:
- · Incident lymphoma initiating treatment with vincristine
- · Planned minimum of 4 cycles of chemotherapy
- Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment
- Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)
- · Written informed consent given
- Enrollment must be completed prior to receiving the first dose of chemotherapy

Exclusion Criteria:

Patients meeting ANY of the following criteria are not eligible for participation:

- Evidence of central nervous system metastases
- Evidence of clinically significant peripheral neuropathy (CTCAE >2) as defined by patient report of frequent numbness or tingling in the hands or feet
- $\bullet \ \text{Any uncontrolled serious illness or medical condition that would impact the conduct of the current study}\\$
- Previous exposure to neurotoxic chemotherapy drugs
- Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury
- General anesthesia less than one month prior to the first dose of neurotoxic chemotherapy

Conditions & Interventions

Interventions:

drug: Vincristine, drug: Paclitaxel, drug: Oxaliplatin, drug: Docetaxel, drug: Bortezomib

Conditions:

Chemotherapy-induced Peripheral Neuropathy

Keywords: CIPN

More Information

Contact(s): There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or - Clinical Trials.gov@lilly.com

Principal Investigator: Smith, Albert Gordon

Phase: N/A IRB

Number: HM20016182 **System ID:** NCT03997981

Thank you for choosing StudyFinder. Please visit http://studyfinder.cctr.vcu.edu to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.